Vanda Pharmaceuticals (VNDA) Revenue (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted Revenue of $51.7 million for Q1 2026, down 9.61% sequentially from $57.2 million in Q4 2025, and up 3.35% YoY from $50.0 million in Q1 2025.
Vanda Pharmaceuticals (VNDA) Revenue (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported Revenue for 17 years, with the latest figure at $51.7 million in Q1 2026.
- Quarterly Revenue rose 3.35% year-over-year to $51.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $217.8 million (up 8.16% YoY) and the FY2025 annual result came in at $216.1 million, up 8.72% from the prior year.
- Revenue retreated to $51.7 million in Q1 2026 per VNDA's latest filing, from $57.2 million in the prior quarter.
- Over five years, Revenue peaked at $65.3 million in Q3 2022 and troughed at $38.8 million in Q3 2023.
- A 5-year average of $53.7 million and a median of $52.6 million in 2025 frame the typical range for Revenue.
- The sharpest annual moves came in 2023 and 2024: Revenue slumped 40.58% in 2023, then grew 22.76% in 2024.
- Over 5 years, Revenue stood at $64.5 million in 2022, then declined by 29.79% to $45.3 million in 2023, then rose by 17.48% to $53.2 million in 2024, then climbed by 7.58% to $57.2 million in 2025, then slipped by 9.61% to $51.7 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $51.7 million, $57.2 million, and $56.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Vanda Pharmaceuticals | 315.57 Mn | 145.54 Mn | 46.97 Mn | 50.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.53 Mn |
| Mar 31, 2026 | 51.72 Mn |
| Dec 31, 2025 | 57.22 Mn |
| Sep 30, 2025 | 56.26 Mn |
| Jun 30, 2025 | 52.59 Mn |
| Mar 31, 2025 | 50.04 Mn |
| Dec 31, 2024 | 53.19 Mn |
| Sep 30, 2024 | 47.65 Mn |
| Jun 30, 2024 | 50.47 Mn |
| Mar 31, 2024 | 47.46 Mn |
| Dec 31, 2023 | 45.27 Mn |
| Sep 30, 2023 | 38.82 Mn |
| Jun 30, 2023 | 46.06 Mn |
| Mar 31, 2023 | 62.50 Mn |
| Dec 31, 2022 | 64.48 Mn |
| Sep 30, 2022 | 65.32 Mn |
| Jun 30, 2022 | 64.39 Mn |
| Mar 31, 2022 | 60.19 Mn |
| Dec 31, 2021 | 68.02 Mn |
| Sep 30, 2021 | 70.10 Mn |